On the Role of Renal α-Adrenergic Receptors in Spontaneously Hypertensive Rats

Martin C. Michel, Sabine Jäger, Rod Casto, Rainer Rettig, Christiane Graf, Morton Printz, Paul A. Insel, Thomas Philipp, and Otto-Erich Brodde

We tested the hypothesis that a genetically determined increase in renal α-adrenergic receptor density might be a pathophysiologically important factor in the spontaneously hypertensive rat model of genetic hypertension. In a first study, we compared renal α1- and α2-adrenergic receptor density with systolic blood pressure in 45 rats of an F2 generation of Wistar-Kyoto×spontaneously hypertensive rat hybrids but were unable to detect significant cosegregation between either receptor density or blood pressure. In a second study, we determined renal α1- and α2-adrenergic receptor density in Wistar-Kyoto and spontaneously hypertensive rat kidneys that were transplanted into an F1 generation of Wistar-Kyoto×spontaneously hypertensive rat hybrids. Although Wistar-Kyoto kidneys lowered blood pressure in these animals and spontaneously hypertensive rat kidneys increased blood pressure, renal α-adrenergic receptor densities were similar in membranes from both types of kidneys. Since rat kidney coexpresses α1A- and α2A-adrenergic receptors, we also investigated whether differential regulation of these two subtypes might conceal ongoing alterations. The α1A/α2A-adrenergic receptor ratio, however, was similar in Wistar-Kyoto rats, spontaneously hypertensive rats, and F1 rats transplanted with a kidney from either strain. Taken together these data do not support the hypothesis that genetically determined alterations of renal α-adrenergic receptor numbers play an important role in the development of elevated blood pressure in the spontaneously hypertensive rat.

KEY WORDS • adrenergic receptors • kidney • radioligand assay • essential hypertension • spontaneously hypertensive rats

Cross-transplantation studies have firmly established a role of the kidney in the development of elevated blood pressure in the spontaneously hypertensive rat (SHR) model of hypertension. Additional data suggest that this may also be the case for one or more subsets of patients with essential hypertension. Another consistent finding in the SHR and in many patients with essential hypertension is an altered function of the sympathoadrenal system. One reflection of this alteration is the repeated finding of an increased number of renal α-adrenergic receptors in SHR; this increase precedes the elevation of blood pressure and is not found in models of acquired hypertension. Since some data link α-adrenergic receptors to the control of renal sodium handling, we hypothesized that a genetically determined alteration of renal α-adrenergic receptors may be an important pathophysiological component in genetic hypertension.

From the Department of Medicine (M.C.M., S.J., T.P., O.-E.B.), University of Essen, Essen, FRG, the Department of Pharmacology (M.C.M., R.C., M.P., P.A.I.), University of California San Diego, La Jolla, Calif, and the Department of Pharmacology (R.R., C.G.), University of Heidelberg, Heidelberg, FRG.

Supported by grant Ph 43/1-1 from the Deutsche Forschungsgemeinschaft and by grants HL-35457 and HL-35847 from the National Institutes of Health.

Address for correspondence: Dr. Martin C. Michel, Nephrol Lab IG 1, Klinikum, Hufelandstrasse 55, D-4300 Essen 1, FRG.

Received August 12, 1991; accepted in revised form November 22, 1991.
generated in the breeding colony at the University of California, San Diego; WKY rats, SHR, and animals for the renal transplantation studies were from the colony at the University of Heidelberg; normotensive Wistar rats for the characterization of renal α1-adrenergic receptor subtypes were from a commercial breeder (Lippische Versuchstierzucht, Extental, FRG). All animals were fed a standard laboratory chow that, according to the manufacturer, contained 0.2% NaCl and were given tap water ad libitum.

The F2 generation of WKY x SHR hybrids was generated from inbred parental strains by crossing breeding male SHR with female WKY rats; animals of the F1 generation were then interbred to generate F2 progeny. After determination of systolic blood pressure by tail plethysmographic method at the age of 17 weeks, 45 female rats of the F2 generation were killed.

Transplantation of WKY and SHR kidneys was performed as previously described. Briefly, kidneys from 16-week-old male WKY rats or SHR were transplanted to 16-week-old F2 hybrids bred from WKY and SHR parents. During surgery for transplantation the recipients were unilaterally nephrectomized, and the second autochthonous kidney was removed 1 week later. Recipients of WKY and SHR kidneys are designated WKY-TX and SHR-TX, respectively. All animals were killed 4 weeks after transplantation following determination of systolic blood pressure by a tail plethysmographic method. We have previously demonstrated that renal grafts from WKY rats and SHR do not significantly differ with regard to renal weight, renal blood flow, glomerular filtration rate, or plasma urea after transplantation.

Membrane Preparation and Binding Assays

Kidneys were decapsulated, rapidly frozen in liquid nitrogen, and stored at −70°C. Two methods were used to prepare renal membranes and perform the binding assays. For the study on the F2 rats, crude renal membranes were prepared by homogenization in a Tissue-mizer (Janke & Kunkel, Staufen, FRG) with subsequent centrifugation at 50,000g for 20 minutes as recently described. For all other experiments, kidneys were homogenized with a motor-driven glass/Teflon homogenizer (Braun, Melsungen, FRG) with a subsequent 1,000g spin followed by a 21,000g spin of the supernatant. The final pellets were resuspended in 50 mM TrisHCl, 0.5 mM EDTA at pH 7.5. The membranes were incubated in a total volume of 1 ml containing six different concentrations of [3H]prazosin (assay for α1-adrenergic receptors) or 0.25 ml (assays for α2-adrenergic receptors) containing six different concentrations of [3H]rauwolscine (F2 study) or [3H]yohimbine (all other experiments). The incubations were performed for 60 minutes ([3H]rauwolscine binding) or 30 minutes (all other experiments) at 25°C and were terminated by rapid vacuum filtration over Whatman GF/C filters; an automatic cell harvester (Biomedical Research and Development Lab, Gaithersburg, Md.) was used in the F2 experiments, whereas a manual vacuum filtration manifold was used in all other experiments. Nonspecific binding was defined as binding in the presence of 10 μM phentolamine. In competition binding experiments, 21 different concentrations of competitor were included in the assay. Protein content was determined by the method of Bradford using bovine immunoglobulin G as the standard. It should be noted that the membrane preparation used is rather crude, but we chose this method to avoid possible selective loss of receptors in one group during the preparation procedure.

Chemicals

Dye reagent for the protein assay was purchased from BioRad, Munich, FRG; oxymetazoline from Sigma, Munich, FRG; [3H]prazosin (specific activity =80 Ci/mmol), [3H]yohimbine (specific activity =80 Ci/mmol), and [3H]rauwolscine (specific activity =80 Ci/mmol) were from New England Nuclear, Boston, Mass., or Dreieich, FRG. The following drugs were gifts of the respective companies: phentolamine (CIBA-GEIGY, Basel, Switzerland) and (+)-niguldipine and 5-methylurapidil (Byk Gulden, Konstanz, FRG).

Data Analysis

Saturation binding isotherms were analyzed by linear regression from Scatchard plots or by nonlinear regression analysis after fitting the data to a rectangular hyperbola; both methods yielded similar results. Competition binding experiments were analyzed by nonlinear regression with the iterative curve-fitting program INPLOT (GraphPAD Software, San Diego, Calif.); a two-site model was assumed if it resulted in a significant improvement of the goodness of fit (assessed by an F test), otherwise a one-site model was assumed. The ratio of $n_{max}/K_A$ for α1-adrenergic receptors was determined from competition binding experiments with highly subtype-selective antagonists. Data are shown as mean±SEM of n experiments. Significances of differences among groups were analyzed by one-way analysis of variance followed by unpaired two-tailed t tests using Bonferroni corrections for multiple comparisons; statistical calculations were performed using the INSTAT program (GraphPAD Software), and a value of $p<0.05$ was considered to be significant.

Results

Studies in an F2 Generation of WKY x SHR Hybrids

As expected, the systolic blood pressures in the F2 generation of SHR x WKY hybrids varied considerably,
Receptor Subtypes

The competition curve for phentolamine was steep with biphasic competition curves that could be resolved into 5-methyl-urapidil, and oxymetazoline yielded shallow further studies to investigate possible differential regulation of α-adrenergic receptor subtypes.

Michel et al α-Adrenergic Receptors in SHR Kidney 367

Characterization of Renal α1-Adrenergic Receptor Subtypes

We used several compounds with known selectivity for α1-adrenergic receptor subtypes to characterize the subtypes present in rat kidney. (+)-Niguldipine, 5-methyl-urapidil, and oxymetazoline yielded shallow biphasic competition curves that could be resolved into high- and low-affinity components (Figure 3, Table 1). The competition curve for phentolamine was steep with a Hill slope not significantly different from unity (1.03±0.18, n=4, Table 1). Since (+)-niguldipine exhibited the greatest selectivity ratio, it was used in all further studies to investigate possible differential regulation of α1-adrenergic receptor subtypes.

Transplantation Study in an F1 Generation of WKY×SHR Hybrids

In this part of our study, we compared renal α1-adrenergic receptors in WKY rats, SHR, and in an F1 generation of WKY×SHR hybrids in which a bilateral nephrectomy and a kidney transplantation from either a WKY rat or a SHR donor had been performed. The systolic blood pressure readings in the four groups were WKY<WKY-TX<SHR-TX<SHR (Figure 4). Thus, a WKY kidney lowers and a SHR kidney raises blood pressure in F1 hybrid recipients.

The density of α1-adrenergic receptors was not significantly different between renal membranes from WKY rats and SHR from the Heidelberg breeding colony (51.7±3.7 versus 48.7±3.7 fmol/mg protein) or between those from WKY-TX and SHR-TX (37.8±2.8 versus 27.2±4.6 fmol/mg protein; Figure 5). However, α1-adrenergic receptor density was significantly lower in WKY-TX compared with WKY and in SHR-TX compared with SHR (Figure 5). The affinities for [3H]prazosin did not differ significantly among groups (WKY, 0.31±0.05 nM; SHR, 0.28±0.03 nM; WKY-TX, 0.23±0.02 nM; SHR-TX, 0.28±0.03 nM). The α1A/α1D-adrenergic receptor ratio did not significantly differ among all four groups (relative amount of α1A-adrenergic receptors: WKY, 58±3%; SHR, 67±2%; WKY-TX, 63±2%; SHR-TX, 62±4%; Figure 6) and was similar to that observed in the prior experiments on renal membranes from normotensive Wistar rats (66±3%, Table 1).

Table 1. Drug Affinities at Rat Renal α1-Adrenergic Receptor Subtypes

<table>
<thead>
<tr>
<th>Drug</th>
<th>pK1-high</th>
<th>pK1-low</th>
<th>% High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenolamine</td>
<td>7.87±0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxybenzocaine</td>
<td>7.55±0.19</td>
<td>5.91±0.17</td>
<td>31±7</td>
</tr>
<tr>
<td>5-Methyl-urapidil</td>
<td>8.90±0.14</td>
<td>7.02±0.00</td>
<td>50±1</td>
</tr>
<tr>
<td>(+)-Niguldipine</td>
<td>9.58±0.32</td>
<td>6.78±0.13</td>
<td>34±3</td>
</tr>
</tbody>
</table>

Data are mean±SEM of four experiments (n=3 for 5-methyl-urapidil) using 0.6 nM [3H]prazosin. Affinity constants are expressed as pK1, i.e., −log of K1 (the affinity constant). The competition curves for phenolamine were steep and could not be resolved into multiple components.
Renal α₂-adrenergic receptors in SHR (90.8±7.4 fmol/mg protein) were only slightly but not significantly higher than in WKY (82.5±10.6 fmol/mg protein, Figure 7). In F₁ hybrids transplanted with a WKY or SHR kidney, similar densities of renal α₂-adrenergic receptors were found that did not differ significantly (WKY-TX, 77.0±6.7 and SHR-TX, 83.5±17.3 fmol/mg protein, Figure 7). The affinity for the radioligand [3H]yohimbine was similar in all four groups (WKY, 5.7±0.7 nM; SHR, 5.9±0.6 nM; WKY-TX, 5.1±0.4 nM; SHR-TX, 7.2±1.5 nM).

Discussion

The present data demonstrate that renal grafts of SHR donors can slightly reduce blood pressure to levels close to those of WKY rats in such recipients. These data confirm previous observations (for review, see Reference 1) from which it can be concluded that information expressed in the kidneys is predominantly if not exclusively responsible for the development of elevated blood pressure in the SHR model of genetic hypertension as well as in certain subsets of essential hypertensive patients.

We previously hypothesized that a genetically determined increase in renal α-adrenergic receptors might participate in the role of the kidney for the development of elevated blood pressure. To link renal α-adrenergic receptors to the development of hypertension, it is important to identify the α-adrenergic receptor subtypes present in this tissue. The shallow biphasic competition curves for [3H]prazosin binding by (+)-niguldipine, 5-methyl-urapidil, and oxymetazoline in the present study demonstrate the presence of two types of α₁-adrenergic receptors in rat kidney. The high affinity...
component for all three drugs corresponds to $\alpha_1\alpha_\text{A}$-adrenergic receptors, whereas the low affinity component identifies $\alpha_1\beta$-adrenergic receptors.\cite{12,13} From our data an $\alpha_1\alpha/\alpha_1\beta$-adrenergic receptor ratio of 40–60 can be calculated. Our data have been obtained by other investigators using isolated renal cells or renal homogenates.\cite{14,15} Previous studies have demonstrated that the $\alpha_2$-adrenergic receptors in rat kidney are predominantly, if not exclusively, of the $\alpha_2\text{A}$-subtype.\cite{9,16-18} Thus, pharmacological means can detect three types of $\alpha$-adrenergic receptors in rat kidney, $\alpha_1\alpha$, $\alpha_1\beta$, and $\alpha_2\beta$-adrenergic receptors. Northern blotting has also confirmed the presence of these three $\alpha$-adrenergic receptor subtypes in rat kidney.\cite{5,6,19} The existence of $\alpha_2\alpha$-adrenergic receptors in rat kidney remains unclear since it is detected by Northern blot analysis\cite{6} but not by radioligand binding.\cite{9,18}

As reviewed previously,\cite{2,4} various laboratories have presented data indicating that an elevation of renal $\alpha$-adrenergic receptors may precede blood pressure increases in SHR but may be absent in animal models of acquired hypertension. The present study sought to examine whether renal $\alpha$-adrenergic receptors cosegregate with blood pressure in the F$_2$ progeny of WKYxSHR hybrids. However, our data fail to detect a significant correlation between either renal $\alpha_1$- or $\alpha_2$-adrenergic receptor density and systolic blood pressure in such animals. Since hypertension in the SHR is likely to be a multigenic disease, the possibility remained that an important contribution of $\alpha$-adrenergic receptors had been overlooked in the crossbreeding studies due to the variation in our measurements in relation to the number of animals studied. Therefore, we undertook studies in renally transplanted animals as a second means to investigate this question.

For several reasons, our data argue against an important role of renal $\alpha_1\alpha$, $\alpha_1\beta$, or $\alpha_2\beta$-adrenergic receptor number for the development of genetic hypertension in SHR: First, SHR and WKY rats from the Heidelberg breeding colony were clearly distinguished by blood pressure but did not exhibit significantly different amounts of $\alpha_1$- or $\alpha_2$-adrenergic receptors. On the other hand, we detect significant increases in renal $\alpha_1$- and $\alpha_2$-adrenergic receptors comparing WKY rats and SHR from a different breeder (Möllegard, Denmark) with the same methods (Reference 20 and data not shown). Previous studies have uniformly detected elevated renal $\alpha_1$-adrenergic receptors in SHR, but increases in renal $\alpha_1$-adrenergic receptors were found in some studies and not in others (as reviewed in References 2 and 4). The fact that SHR from various breeders are clearly hypertensive but only some exhibit increased $\alpha_1$- or $\alpha_2$-adrenergic receptors argues against an important role for such changes. Second, SHR kidneys that can induce hypertension in immunotolerant recipients do not have a major pathophysiological role in the development of genetic hypertension in the SHR. Alterations of $\alpha_1\alpha$-adrenergic receptors, however, may be important in the SHR and may also play a role in human hypertension. Further studies are needed to establish the role of possible alterations of $\alpha$-adrenergic receptor function in hypertension.

Note added in proof. Using the novel radioligand $[^{3}\text{H}]RX821002$, detection of $\alpha_2\alpha$-adrenergic receptors in rat kidney has recently become feasible.\cite{26}

References

On the role of renal alpha-adrenergic receptors in spontaneously hypertensive rats.
M C Michel, S Jäger, R Casto, R Rettig, C Graf, M Printz, P A Insel, T Philipp and O E Brodde

Hypertension. 1992;19:365-370
doi: 10.1161/01.HYP.19.4.365

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1992 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/19/4/365

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in
Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located, click
Request Permissions in the middle column of the Web page under Services. Further information about this
process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/